NIH R01 · 2025
Project Summary Background: Dolutegravir (DTG) is a first-line antiretroviral drug used in combination therapy for the treatment of human immunodeficiency virus type-1 (HIV-1) infection. Due to the roll out of generic DTG-based regimen, its inclusion in national treatment guidelines and rising pretreatment resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource limited countries, in just 5 years, 15 million HIV-1 infected people will be treated with DTG. This includes women of child-bearing age, who remain a significant infected population (UNAIDS data, 2021). However, during recent years, growing data from clinical and pre-clinical studies have suggested that DTG…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.